[1] The efficacy and safety of young blood transfusions for anti-aging purposes remain a subject of debate in the scientific community, with limited clinical evidence in humans.
[4][5][6][7][8][9] The U.S. Food and Drug Administration, in 2019, cautioned "consumers against receiving young donor plasma infusions" stating that they are an "unproven treatment".
[10] Amy Wagers, a researcher who coauthored several mouse studies on young blood transfusion, has said that her papers do not provide a scientific basis for some of the existing human trials.
A 2023 study reported that the existing rheumatoid arthritis drug anakinra blocked IL-1B in elderly mice and returned those cells to a more youthful state.
There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials.
[23] David Wright is the licensed doctor overseeing the clinical trial; in his practice he administers intravenous treatments of vitamins and antibiotics for nontraditional purposes and was disciplined by the California Medical Board for the latter in 2015.
Jonathan Kimmelman, a bioethicist from McGill University, suggests that Ambrosia is running this as a trial as they would be unable to get FDA approval to sell this treatment otherwise.
As of 2017 it is collaborating with European pharmaceutical company Grifols to create a blood plasma-based experimental biologic drug which they propose to test on people with Alzheimer's.